Detail of "7753-60-8"

Reference

Anecortave acetate in the treatment of age-related macular degeneration

All Rights Reserved. Anecortave acetate in the treatment of age-related macular degeneration. Augustin, Albert (Department of Ophthalmology, Karlsruhe 76133, Germany). Clinical Interventions in Aging, 1(3), 237-246 (English) 2006 Dove Medical Press (NZ) Ltd. CODEN: CIALBC. ISSN: 1176-9092. DOCUMENT TYPE: Journal; General Review CA Section: 1 (Pharmacology) A review. RETAANE 15mg (anecortave acetate suspension) is under investigation to treat exudative age-related macular degeneration (AMD), the single largest cause of blindness in the Western world, affecting over 15 million people in the USA. RETAANE suspension is a unique synthetic cortisene and has antiangiogenic properties that were established in multiple exptl. models of angiogenesis. The mol. acts at multiple sites of the angiogenic cascade. Clin. 129497-78-5 and 7753-60-8 are also in the experiment. trials in patients with exudative AMD have demonstrated the excellent safety record of both the drug anecortave acetate and the posterior juxtascleral depot (PJD) administration procedure. A pivotal study comparing RETAANE suspension with placebo showed a significantly higher chance of maintaining vision in the treatment (73%) as compared with placebo (47%). Another study compared RETAANE suspension with Visudyne photodynamic therapy, revealing no statistically significant differences between the two treatments over 24 mo. AMD is a multi-faceted disease and therefore a mol. such as RETAANE suspension with a unique mechanism of action, demonstrated clin. efficacy, and retreatment every six months is an important potential treatment option which should be further investigated both as a monotherapy or in combination with other treatment strategies. .

Protection of visual acuity in patients with age related macular degeneration by administration of anecortave acetate

Protection of visual acuity in patients with age related macular degeneration by administration of anecortave acetate. Jerdan, Janice A.; Zilliox, Patricia; Robertson, Stella M. (Alcon, Inc., Switz.). PCT Int. Appl. WO 2004012742 A1 12 Feb 2004, 29 pp. DESIGNATED STATES: W: AU, BR, CA, CN, JP, KR, MX, PH, PL, RU, US, ZA; RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR. (English).Several substances with their cas registry numbers 7753-60-8 and 10184-70-0 may be metioned in this study. (World Intellectual Property Organization). CODEN: PIXXD2. CLASS: ICM: A61K031-56. APPLICATION: WO 2003-US20154 26 Jun 2003. PRIORITY: US 2002-PV401220 5 Aug 2002. DOCUMENT TYPE: Patent CA Section: 2 (Mammalian Hormones) Section cross-reference(s): 1 The invention discloses the use of anercortave acetate or the alc. thereof for the protection of visual acuity in patients with age related macular degeneration. .